Raymond James Trust N.A. boosted its position in Bioverativ Inc (NASDAQ:BIVV) by 16.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,072 shares of the biotechnology company’s stock after buying an additional 855 shares during the period. Raymond James Trust N.A.’s holdings in Bioverativ were worth $328,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of BIVV. Robeco Institutional Asset Management B.V. bought a new stake in Bioverativ in the 4th quarter valued at about $105,000. American Assets Investment Management LLC bought a new stake in Bioverativ in the 4th quarter valued at about $108,000. Advisors Asset Management Inc. bought a new stake in Bioverativ in the 3rd quarter valued at about $137,000. TCI Wealth Advisors Inc. bought a new stake in Bioverativ in the 3rd quarter valued at about $186,000. Finally, Ladenburg Thalmann Financial Services Inc. bought a new stake in Bioverativ in the 3rd quarter valued at about $190,000. 95.14% of the stock is owned by institutional investors and hedge funds.

BIVV has been the subject of a number of research analyst reports. Royal Bank of Canada boosted their target price on Bioverativ to $68.00 and gave the company a “market perform” rating in a research report on Thursday, January 18th. Zacks Investment Research downgraded Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Jefferies Group lifted their price target on Bioverativ to $79.00 and gave the company a “buy” rating in a research note on Thursday, January 18th. Raymond James Financial downgraded Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $65.00 price target on shares of Bioverativ in a research note on Thursday, January 18th. Thirteen investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $63.15.

Bioverativ Inc (NASDAQ:BIVV) opened at $103.14 on Friday. Bioverativ Inc has a 12 month low of $41.88 and a 12 month high of $104.30.

WARNING: “Bioverativ Inc (BIVV) Shares Bought by Raymond James Trust N.A.” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/bioverativ-inc-bivv-shares-bought-by-raymond-james-trust-n-a/1854561.html.

Bioverativ Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.